Genedata Screener

Genedata Screener® is an enterprise software platform designed to automate assay analysis, validate raw data and assay result quality, and consolidate screening information across the enterprise and external collaborators. By integrating and condensing complex experimental data from any therapeutic modality—including biotherapeutics and small molecules—across any disease area, it accelerates project decisions and lays the foundation for more predictive, AI-powered drug discovery and development.

Built for biopharmaceutical organizations, Genedata Screener empowers scientists and research-IT teams to make faster, insight-driven decisions by unlocking the full potential of multimodal screening data. It eliminates manual bottlenecks, ensures high data quality and reproducibility, and integrates seamlessly into evolving R&D environments to enable more effective collaboration across global teams and external partners.

Supported Assay Applications

• High-Throughput Screening: Supports scalable screening using biochemical, biophysical, and cellular assays, as well as advanced modalities including label-free technologies such as high-throughput mass spectrometry, covering the full workflow from primary screening through hit validation and lead development.
• Large Molecule Assays: Accelerates large molecule discovery across multiple R&D stages, supporting plate-based immunoassays, cellular assays, high-throughput flow cytometry, epitope binning, and biophysical assays such as surface plasmon resonance (SPR) and bio-layer interferometry (BLI).
• High-Content Assays: Provides an end-to-end solution for image-based high-content screening (HCS), combining target-agnostic approaches, physiologically relevant models, and information-rich imaging to streamline data interpretation and enable consistent application across the discovery pipeline.
• Multiplexed Assays: Streamlines quality control and analysis of multidimensional results from multiplexed assays—including flow cytometry, transcriptomic profiling, and combination screening—enabling deeper insights from tens to hundreds of measurements per sample.
• Biophysical Characterization & Screening: Simplifies characterization of molecular interactions and stability using technologies such as impedance, SPR, BLI, and thermal shift assay (TSA), with ready-to-use workflows that eliminate repetitive tasks and enable seamless data integration across plates and instruments.
• Pharmacological & Mechanistic Analysis: Automates and harmonizes in vitro ADME-Tox, kinetic characterization, and mechanism-of-action studies, enabling rigorous target engagement studies early in the discovery pipeline to mitigate risk and increase the likelihood of success.

Core Platform Capabilities

• Automation: Enables seamless retrieval of assay data and metadata from instruments, automated analysis and quality control, and centralized reporting to global teams, providing a digital backbone for the modern lab with FAIR (findable, accessible, interoperable, reusable) and AI-ready data.
• Assay Data Management & Decision-Making: Organizes, annotates, and harmonizes assay data from internal teams and external collaborators, laying the foundation for AI-powered predictions and confident, data-driven decision-making.
• Seamless Integrations: Connects with a wide range of instruments and software used in screening workflows—from plate readers and imaging systems to ELNs and LIMS—through open architecture and flexible APIs that enable automated data flow and reduce manual effort.

Key Platform Strengths

• Centralized Screening Data: Unifies all screening data in a scalable, modality-agnostic platform with scientifically validated workflows, predefined analysis steps, controlled vocabularies, and structured data management that makes results findable, accessible, and ready for downstream use.
• Accelerated Discovery at Scale: Processes large, complex datasets in minutes with automated data capture, calculations, and multi-level quality control. Intuitive wizards, raw data import, automated curve-fitting, model selection, and multiplexing deliver per-molecule results faster to identify promising leads earlier.
• High-Quality, Reproducible Results: Applies standard QC criteria, flags suspect data, and enables interactive review of analysis parameters. Any adjustments trigger automatic recalculation across entire datasets, while advanced fitting algorithms and validated models minimize manual errors and provide dynamic visualizations for additional QC.
• Seamless Collaboration: Centralizes assay data for instant access across departments, disciplines, and global sites, keeping biologists, chemists, and data scientists aligned on a unified data foundation with secure, cloud-based access for distributed teams and external partners.
• GxP and Regulatory Compliance: Ensures data integrity, traceability, and inspection-ready processes through validation-ready workflows, SOP integration, and standardized processes. Sensitive data is protected via encryption, role-based access, and secure deployment options, with immutable records and complete audit logs for long-term traceability.
• Scalable, Adaptable Architecture: Evolves with changing screening environments, supporting diverse formats including Ion Channel, Kinetic, Mass Spectrometry, and High-Content Screening, and scales with changing requirements without custom development.

Genedata Screener supports both on-premise and cloud-based secure deployment options and integrates with imaging systems, lab software, ELNs, and LIMS through flexible APIs. The platform is designed to meet the needs of regulated environments, supporting GxP compliance and providing the traceability required throughout the R&D lifecycle.